Here are the remaining 2006 events on our
clinical/regulatory calendar. If anyone knows that
something here is out of date, please chime in.
AMGN – Vectibix final OS from ‘408’ study.
ANOR, AOM.TO – pivotal AMD3100 results.
COLY – 12-week interim data from the lead Actilon trial, the phase-2 for null responders.
CORT – Phase-3 ‘06’ trial of Corlux for psychotic major depression.
GILD – Start phase-1 for GS9190 in HCV.
GTCB – Start phase-2 ATryn trial in DIC by Leo Pharma.
NRMX, NRM.TO – Complete enrollment in European Alzhemed trial.
TELK – ASSIST-1 -2 and -3 results (to be announced simultaneously).
YMI – AeroLEF final results.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”